Practical AI in Healthcare

S1, E38 - Reflections 5: How Specialized Does AI Have to Be to Actually Work?

In their fifth Reflections episode, Steve and Leon look back across six conversations (Matt Truppo at Sanofi, Ted Shortliffe, Barry Chaiken, David Hidalgo-Gato, and Danny van Leeuwen) to ask a sharper question: how specialized does AI have to be to actually work? The throughline is depth. The LLM is a commodity, and so, increasingly, is the generalist agent. What stays scarce is specialization in a workflow, the revival of symbolic methods like knowledge graphs, the literacy that separates an AI's ~95% solo accuracy from the under-35% people get using it themselves, and leaders willing to use themselves as the test rig. After 37 episodes, the technology is no longer the question. The specificity of the work around it is.

S1, E37 - Danny van Leeuwen, MPH, RN, Health Hats: Patient's POV on AI Tools

Danny van Leeuwen is a nurse of 50 years, a multiple sclerosis patient, host of the Health Hats podcast, and a serial member of national outcomes panels at CMS, AHRQ, PCORI, and the National Academy of Medicine. He has tried more than 100 health apps and uses five. In this episode, he explains how he uses AI to interrogate his own chart, surface symptom patterns, and prepare for clinical encounters, and he shares his Three T's and Two C's framework for evaluating any digital health technology: Time, Trust, Talk, Control, Connection. The conversation covers what patients want from AI, what they do not, and why pain, fear, and cognition still escape the data.

S1, E36 - David Hidalgo-Gato, Founder & CEO, Cleo Health: Going a Mile Deep on Emergency Medicine — Specialization, Design Partnerships, and the Acute Care OS

David Hidalgo-Gato is the founder and CEO of Cleo Health. While more than 100 competitors were building generic ambient AI scribes, David's team chose emergency medicine and stayed with one design partner for nine months and roughly 50 product iterations before launching. The result: an average 54-minute time savings per shift, a patient-assignment tool that turned a four-hour process into 15 to 20 minutes, and use across 400+ hospitals nationwide. The conversation covers why ED workflow breaks generic ambient scribes, why generative AI fits patient assignment specifically, and David's argument that workflow understanding is the moat AI cannot commoditize. https://practicalaiinhealthcare.com/ [https://practicalaiinhealthcare.com/]

S1, E35 - Barry P. Chaiken, MD, MPH: Physician-as-Patient Perspective on AI in Healthcare

When physician Barry Chaiken was diagnosed with prostate cancer, his clinical training gave way to fear. It took a friend asking, "What are you doing?" to snap him back into doctor-mode thinking. That experience reshaped how he sees AI in healthcare. In this episode, Chaiken draws on his dual perspective as physician and two-time cancer survivor to argue that consumer health AI is failing patients, not because the models are bad, but because patients don't know how to use them. He shares a practical framework for AI-assisted patient education, makes the case for an aviation-style safety reporting system for healthcare AI, and explains why interoperability is an incentive problem, not a technology problem.

S1, E34 - Matt Truppo, PhD, Part 2: AI-Driven Drug Development at Sanofi: Clinical Trials, Regulatory, and Personal AI

In Part 2 of our conversation with Matt Truppo, Global Head of Research Platforms and Computational R&D at Sanofi, we move from discovery to development, where the real stakes begin. Matt unpacks the promise and limitations of “digital patient twins,” a concept often described as the holy grail of drug development. With nearly 90% of drugs failing in clinical trials, even modest gains in predicting efficacy or patient response could transform the industry. Through real-world examples, including Dupixent and rare disease therapies, Matt shows how quantitative systems pharmacology (QSP) and AI-driven simulations are already shortening timelines, reducing patient burden, and, in some cases, eliminating the need for entire trials. But the story doesn’t stop at modeling. We explore how AI is reshaping clinical operations, from Sanofi’s “clinical control tower” that integrates trial data across 4,000 users, to generative AI tools that are cutting regulatory document creation time by more than a third. Matt also shares a personal experiment, building a network of AI agents modeled on his own workflow, reclaiming 30% of his time and offering a glimpse into a more “agentic” future of work. The throughline is clear: AI is not replacing human expertise, but amplifying it, helping the industry finally bend the cost and time curve of drug development.